Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization277 mentions
- NVIDIAorganization265 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
systemic lupus erythematosus treatment
market5 mentionslast seen Nov 12, 2026
Treatment of systemic lupus erythematosus, an autoimmune disease.
Relationships 5
- velinotamigapplies tosystemic lupus erythematosus treatment99% confidence2 sources
- CLN-978applies tosystemic lupus erythematosus treatment95% confidence1 source
- budoprutugapplies tosystemic lupus erythematosus treatment94% confidence1 source
- telitaciceptapplies tosystemic lupus erythematosus treatment93% confidence1 source
- prulacabtagene leucelapplies tosystemic lupus erythematosus treatment90% confidence1 source
Relationship
velinotamigapplies tosystemic lupus erythematosus treatment
99% confidence2 supporting mentions
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGARNov 9, 2026Cullinan Therapeutics, Inc. 8-K: Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Phase 1b/2a study of velinotamig (GR1803) in patients with active, refractory, moderate-to-severe systemic lupus erythematosus (SLE)
- filingSEC EDGARSep 24, 2026Cullinan Therapeutics, Inc. 8-K: Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Velinotamig (BCMAxCD3 T cell engager): treatment-refractory autoimmune diseases driven by long-lived plasma cells... Phase 1 dose escalation study in SLE